Argenx to buy Forte Biosciences for $2.2 billion

The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.
Barchart on MSN

The charts reveal significant price movement in Forte Biosciences stock ahead of Argenx’s acquisition announcement

Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. ・FBRX saw significant price ...

Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among ...
pharmaphorum

Argenx pens $2.2bn deal to buy autoimmune biotech Forte

Netherlands- and Belgium-based biotech argenx has agreed to buy US biotech Forte Biosciences for up to $2.2 billion, ...

Forte: 'Hold' On Positive FB102 Vitiligo Treatment Data And argenx Acquisition For $2.2 Billion

Forte Biosciences is being acquired by Argenx for $2.2 billion [$77/share], capping near-term upside. Click here to read my ...

Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx

Forte Biosciences (NASDAQ:FBRX) shares climbed 39. 2% in pre-market trading after argenx (NASDAQ:ARGX) announced a definitive agreement to acquire the clinical-stage biotechnology company in an ...

argenx To Acquire Forte Biosciences: What Investors Should Know

SE’s $2.2B Forte Biosciences, Inc. deal adds FB-102 to expand pipeline, but valuation & Vyvgart patent risks raise caution.

Kia Forte

Get in-depth unbiased information on the Kia Forte from Consumer Reports including major redesigns, pricing and performance, and search local inventory ...

Argenx to buy Forte Biosciences for about $2.2 billion

July 27 (Reuters) - Belgian-Dutch immunology company argenx will buy Forte Biosciences to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday. Argenx will pay $77 a ...